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Abstract
Cancer is currently one of the leading causes of death worldwide and is one of the most challenging major public
health problems. The main challenges faced by clinicians in the management and treatment of cancer mainly arise
from difficulties in early diagnosis and the emergence of tumor chemoresistance and metastasis. The structures of
chemokine receptor 9 (CCR9) and its specific ligand chemokine ligand 25 (CCL25) have been elucidated, and,
interestingly, a number of studies have demonstrated that CCR9 is a potential tumor biomarker in diagnosis and
therapy, as it has been found to be highly expressed in a wide range of cancers. This expression pattern suggests
that CCR9 may participate in many important biological activities involved in cancer progression. Researchers
have shown that CCR9 that has been activated by its specific ligand CCL25 can interact with many signaling
pathways, especially those involved in tumor chemoresistance and metastasis. This review, therefore, focuses
on CCR9 induction activity and summarizes what is currently known regarding its role in cancers and its potential
application in tumor-targeted therapy.
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Background
Chemokines are a class of small proteins with molecular
weights of approximately 8–14 kDa that, once combined
with their homologous receptors, can activate and che-
moattract leukocytes. Chemokine receptors are G protein-
coupled receptors with seven transmembrane domains.
Chemokines and their receptors play vital roles in the
migration of thymocytes and maturation in normal and
inflammatory environments. At the same time, they have
great potential for use in tumor-targeted therapy [1, 2] in
which, cancer-related chemokines could promote tumor
proliferation, angiogenesis, and chemoresistance [3–5]. In
the past decade, chemokine ligand 25 (CCL25)/chemokine
receptor 9 (CCR9) have been found in a wide variety of
tumors and have been associated with tumor chemoresis-
tance and metastasis. This review will examine the expres-
sion of CCR9 in cancer, recent insights into the
mechanisms of CCL25/CCR9 that are involved in tumor
chemoresistance and metastasis, and the potential applica-
tion of CCR9-based targeted therapy.
Structure and characteristics
CCR9
CCR9 is located on chromosome 3p21.31 and belongs to
the β-chemokine receptor family. It consists of tran-
scripts A (369 amino acids, 42 kDa) and B (357 amino
acids, 40.8 kDa). The molecular structure of CCR9 (44
to 241 amino acids) is shown in Fig. 1a. CCR9 is mainly
distributed in immature T lymphocytes and on the sur-
face of intestinal cells, and it plays a role in T lympho-
cyte development and tissue-specific homing when
bound to its specific ligand.
CCL25
CCL25, also known as thymus-expressed chemokine
(TECK), belongs to the CC chemokine family and is the
specific ligand for CCR9. CCL25 is located on chromo-
some 19p13.2 and consists of isotype 1 (150 amino
acids, 16.6 kDa), isotype 2 (84 amino acids, 9.5 kDa),
and isotype 3 (149 amino acids, 16.5 kDa). The molecu-
lar structure of CCL25 (28 to 93 amino acids) is shown
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in Fig. 1b. The simulated interaction between CCL25
and CCR9 is shown in Fig. 1c.
The expression of CCR9 in cancer
Several studies have found that CCR9 is highly expressed
in a variety of cancers (Table 1). These studies have
confirmed that various factors lead to the upregulation
of CCR9, such as TNF-α, which promotes CCR9
expression in human breast cancer MCF-7 cells [6],
Notch signaling has been observed to induce CCR9
upregulation, which plays a vital role in T-lineage
acute lymphoblastic leukemia (T-ALL) [7]. Moreover,
we are finding that certain non-coding RNAs, such as
miRNA and lncRNA, can mediate the expression of
CCR9 and further affect its biological function.
The pathway of CCL25/CCR9 in cancer
With recent statistics showing that one in four deaths in
the USA is due to cancer [8]. Cancer mortality remains
high, while the number of cancer survivors continues to
Fig. 1 The structures of CCR9 and CCL25. The molecular structures of CCR9 (a) and CCL25 (b) from the UniProt web site (http://
www.proteinmodelportal.org/query/uniprot). The simulated interaction of CCL25 and CCR9 was performed by MGLTools 1.5.6 software
based on the structures of CCR9 and CCL25 (c)
Table 1 The expression of CCR9 in cancer patients
Tumors Cell type Methods Expression References
T-ALL PBMCs (n = 21) FCM 91.9 % [25]
Melanoma Circulating tumor cells (n = 21) FCM 57 % [58]
Melanoma Primary specimens (n = 32) IHC 69.7 % [59]
Melanoma metastasis Small intestinal metastases (n = 102) QPCR 86 % [30]
Mediastinal large B cell lymphomas Lymphoid tissue (n = 22) IHC 90.9 %a [60]
Large B cell lymphoma Gastric extranodal diffuse lymphoma (n = 10) IHC 58.33 % [61]
Large B cell lymphoma Gastrointestinal lymphoma (n = 41) IHC 66 %b [62]
Ovarian cancer Cancer tissues (n = 43) IHC Significantly higher [11]
Lung cancer Lung biopsies (n = 50) WB 1.2c [63]
Hepatocellular carcinoma Cancer tissues (n = 240) IHC 55.8 % [9]
Breast cancer Moderately differentiated cancer tissues (n = 18) IHC 50 % [64]
Poorly differentiated cancer tissues (n = 18) IHC >75 %
Colon cancer Adenomatous foci (n = 46) IHC 2.26 ± 0.06d [65]
Nasopharyngeal carcinoma Carcinoma tissues (n = 42) IHC 80.95 % [66]
FCM flow cytometry, PBMC peripheral blood mononuclear cell, QPCR quantitative polymerase chain reaction, IHC immunohistochemistry, WB western blot
aProportion of positive tumor cells >50 % (20/22)
b3+ CCR9 staining
cControl tissue (n = 50), CCR9/β-actin <0.3
dNormal colon epithelium had a mean staining intensity of 1.60 ± 0.04 (n = 55)
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increase. Some of the challenges faced by clinicians in
the management and treatment of cancers include dif-
ficulties in diagnosing cancer in the early onset stages
and the emergence of tumor chemoresistance and
metastasis.
Recently, researchers have focused on CCR9 expres-
sion in selected cancers and on how CCR9 expression
can be manipulated as a potential tumor biomarker in
cancer diagnosis and treatment. The interaction of
CCL25/CCR9 has been shown to activate many signaling
pathways in cancer, especially those involved in tumor
chemoresistance and metastasis. Therefore, in this re-
view, we focus on CCR9 as a potential tumor biomarker
and on how the CCL25/CCR9 pathway is involved in
tumor chemoresistance and metastasis.
CCR9 as a tumor biomarker
CCR9 expression has been shown to be increased in
various cancers, and CCR9 is specifically expressed in
certain tissues. Studies have revealed that ectopic expres-
sion of CCR9 may be mediated by the downregulation of
p21 and p27 and upregulation of cyclin D1 to enhance
cell proliferation and tumorigenicity in hepatocellular
carcinoma cells. Additionally, the ectopic expression of
CCR9 has been shown to be an independent prognostic
factor for the overall survival of hepatocellular carcin-
oma patients [9]. Other researchers have shown that the
upregulation of CCR9 was associated with a poor re-
sponse to infliximab, which is an anti-tumor necrosis
factor-α (TNF-α) antibody drug used in psoriasis pa-
tients. Therefore, CCR9 expression can act as a novel
prognostic marker and therapeutic target for hepatocel-
lular carcinoma [9] and may be a useful biological
marker of the clinical efficacy of infliximab therapy in
psoriasis patients [10].
CCL25/CCR9 induces tumor chemoresistance
CCL25/CCR9 causes conformational change of PI3K dimers
to activate PI3K/AKT pathway
The interaction of CCL25/CCR9 can cause conform-
ational changes that allow PI3K dimers to activate PI3K.
Activated PI3K on the plasma membrane can produce a
second messenger (PIP3) that binds with the intracellu-
lar AKT PH domain and phosphoinositide-dependent
kinase (PDK) 1 to phosphorylate AKT at Thr308 and
PDK2 to phosphorylate AKT at Ser473. Activated AKT
can activate the phosphorylation of NF-κB or mTOR
signaling molecules, or it can inhibit its downstream tar-
get protein, GSK-3β, to mediate cancer proliferation and
apoptosis [11–13]. Recent studies have shown that
CCL25/CCR9, via activating the PI3K/AKT signaling
pathway, mediated anti-apoptotic processes in lung can-
cer [12], induced etoposide resistance in prostate cancer
[14], and induced cis-platinum resistance, which is
dependent on PI3K and not FAK, in breast and ovarian
cancer [15, 16].
CCL25/CCR9 enhances the interaction of P-gp and ERM to
increase drug efflux
We found that CCL25/CCR9 involvement in the
resistance of TNF-α-induced apoptosis in T-ALL de-
pends on Livin, thus suggesting that CCL25/CCR9
plays an anti-apoptotic role [17]. Furthermore, we ob-
tained a multi-resistant T-ALL cell line, MOLT4/
DOX, which was derived from MOLT4 (which has a
naturally high expression of CCR9) through doxorubi-
cin dosing screening. Then, we investigated this multi-
resistant cell line and found that CCR9 induces resist-
ance to chemotherapy drugs, which could be blocked
by CCR9 antibodies. We confirmed that CCL25/CCR9
influences the interaction of P-gp and the cytoskeleton
protein ERM to increase P-gp efflux, thus mediating T-
ALL tumor chemoresistance [18].
CCL25/CCR9 mediates STAT signaling to weaken cytotoxic
effect
Tumor resistance to cytotoxic T lymphocytes mainly
limits T cell tumor immunotherapy. Khandelwal and
colleagues performed a siRNA rapid high-throughput
screen and found that in T cells, STAT signaling path-
ways were mediated by CCR9 and affected Th1 cytokine
secretion to weaken the cytotoxic effect. Therefore, inhi-
biting CCR9 expression in vivo could significantly
improve the effect of tumor-specific T cell-mediated im-
mune therapy [19].
CCL25/CCR9 activates β-catenin to induce tumor
chemoresistance
CCR9-mediated activation of β-catenin and the result-
ing downstream effects were effectively inhibited by
blockade of the PI3K/AKT pathway. Further, β-catenin
activation induced by CCR9 increased the expression of
Cyclin E1, Cyclin D1, and E-Cadherin to increase the
lethal dose of gemcitabine in pancreatic cancer, sug-
gesting that CCR9/β-catenin signaling enhances pan-
creatic cancer chemoresistance [20]. A diagram of the
mechanism of CCR9-mediated tumor chemoresistance
is shown in Fig. 2.
CCL25/CCR9 induces tumor metastasis
CCL25/CCR9 increases the expression of MMP2 and MMP9
to degrade collagen type IV
The degradation of the extracellular matrix and basilar
membrane is a key step in the process of cancer cell
invasion and metastasis that mainly involves matrix me-
talloproteinases (MMPs). MMPs are proteolytic enzymes
that are closely associated with tumor metastasis. Most
MMPs contain an affiliate area to adjust the catalytic
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activity and identify the substrate, while others have af-
filiate areas that have no catalytic activity but can play a
role in tumor progression. For example, MMP-2 and
MMP-9 have three fibronectins, which repeatedly inserted
in the catalytic area to connect the substrates gelatin,
collagen, and laminin. Therefore, MMP-2 and MMP-9
can degrade collagen type IV, which is a major component
of the basilar membrane. Studies have found that the
interaction of CCL25/CCR9 can increase the expression
of MMP-2 and MMP-9, which induce tumor metastasis in
a variety of cancers, such as ovarian cancer [21], prostate
cancer [22], non-small cell lung cancer [23], and endomet-
riosis [24].
CCL25/CCR9 induces cancer cells polarization and microvilli
absorption
Our previous study found that CCR9 is highly expressed
in CD4+ T cells from T-ALL patients, with little or no
expression in normal T cells. The chemotaxis and adhe-
sion effects on leukemia cells were ablated when CCR9
was internalized on the T-ALL CD4+ T cells, which sug-
gests that CCR9 is closely related to the infiltration and
metastasis of leukemia cells [25]. Further studies showed
that CCL25/CCR9 induces MOLT4 cell polarization and
microvilli absorption to participate in leukemia infiltra-
tion and trafficking via the RhoA-ROCK-MLC and ezrin
pathway [26, 27]. A diagram of the mechanism of
CCR9-mediated tumor metastasis is shown in Fig. 3.
Paracrine CCL25 induces tumor metastasis
Most cancer cells upregulate CCR9 to mediate metasta-
sis, and some cancers secrete CCL25 in a paracrine fash-
ion; these cells include pancreatic cancer PSCs and
PANC-1 cells, which then induce metastasis by binding
the secreted CCL25 to CCR9 receptors in the nearby tis-
sues [28]. The mechanism of metastasis remains unclear.
CCR9 as a lymphocyte homing receptor
Chemokine receptors can also act as homing receptors
for chemotaxis-specific cell homing to specific positions.
Studies have shown that CCR9 is highly expressed in
melanoma skin lesions [29], and that melanoma cells are
specifically targeted to the small intestine when CCL25/
CCR9 signaling is activated [30, 31]. In addition, CCR9
is highly expressed in adult lymphoblastic leukemia cells,
and the CD4+ T cells that infiltrate the gastrointestinal
tract show high CCR9 expression as detected by immu-
nohistochemistry, suggesting that the infiltration of
leukemia cells into the intestine is closely related to
CCR9 expression in patients [32].
CCL25/CCR9 inhibits the bioactivity of PTEN gene
The expression of cytokines in the cancer microenviron-
ment can affect the PTEN gene. It has been observed
that CCR9-induced tumor proliferation and migration
activity is increased with the loss of PTEN in T-ALL
models, suggesting that PTEN loss can inhibit tumor
Fig. 2 Diagram summarizing the reviewed mechanisms by which CCR9 induces different aspects of tumor chemoresistance. The interaction of
CCL25/CCR9 can induce tumor chemoresistance via the PI3K-AKT-(GSK-3β/mTOR/NF-κB/β-catenin) and JAK-STAT pathways. The interactions be-
tween P-gp, ERM, and F-actin can induce tumor chemoresistance via the CCL25/CCR9 pathway
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metastasis [33]. Therefore, the mechanisms of CCL25/
CCR9-induced tumor metastasis are complex and re-
quire further research.
The different signaling pathways of CCL25/CCR9 that
are involved in cancer chemoresistance and metastasis
are shown in Table 2, and a diagram of the mechanism
of CCR9-mediated tumor chemoresistance and metasta-
sis is shown in Fig. 4.
Targeted therapy research
When we identify a molecule that is highly expressed
in cancer and rarely expressed in normal tissues, it is
important to know whether there is clinical value to
this information. Some researchers have developed an
anti-CD19 monoclonal antibody with high killing ac-
tivity against B cell malignancies, acute lymphoid
leukemia, and B-ALL cells based on a specific B cell
marker (CD19) [34–36]. Debra and colleagues found
that anti-HuD-based immunotoxin therapy might be
an effective alternative treatment for patients with
small cell lung cancer and neuroblastoma because the
HuD antigen is expressed in 100 % of small cell lung
cancer cells and in over 50 % of neuroblastoma cells
[37]. Presently, others and we found that CCR9 is
highly expressed in various cancers (Table 1), and have
focused on targeting therapy based on CCR9.
CCR9 antibody
A number of studies have developed chemokine
receptor-specific monoclonal antibodies as potential
targeted therapies based on the important roles of
chemokines and their receptors, such as CXCR4 [38],
CXCR5 [39], CCR4 [40], and CCR7 [41] in cancer.
Chamorro and colleagues identified and developed a
Table 2 The signaling pathway of CCL25/CCR9 in cancer chemoresistance and metastasis
Pathway Reference
Tumor chemoresistance PI3K/AKT Lung cancer [12], prostate cancer [14], breast cancer [15], ovarian cancer [16]
P-gp/ERM/F-actin T-ALL [17, 18]
STAT Breast cancer [19]
β-catenin/cyclin Pancreatic cancer [20]
Tumor metastasis MMPs Ovarian cancer [21], prostate cancer [22], non-small cell lung cancer [23], endometriosis [24]
RhoA-ROCK-MLC/ezrin T-ALL [26, 27]
Paracrine of chemokines Pancreatic cancer [28]
Lymphocyte homing Melanoma [29, 31], lymphoblastic leukemia [32]
PTEN signaling T-ALL [33]
Fig. 3 Diagram summarizing the reviewed mechanisms by which CCR9 induces different aspects of tumor metastasis. a The interaction of CCL25
and CCR9 can induce tumor metastasis via the RAS-MAPK-MMP pathway, the RhoA-Rock-MLC pathway, and ezrin signaling. b CCR9-high-
expressing tumor cells are targeted to the small intestine and gastrointestinal tract by CCL25/CCR9 signaling. The solid arrows indicate that these
signaling pathways have confirmed; the dashed arrows show that these signaling pathways need to be further validation
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mouse anti-human CCR9 IgG2b monoclonal antibody
(91R) that can recognize an epitope within the CCR9
N-terminal domain and that inhibits the growth of
subcutaneous xenografts in mice with an 85 % reduc-
tion in tumor size compared with controls. Tumor
reduction was consistent, and apoptotic cells and
tumor necrotic areas increased as the number of pro-
liferating cells decreased in 91R-treated mice [42].
Immunotoxin
Drug-targeted therapy is usually selective for specific sys-
tems, organs, tissues or cells, and this plays an important
role in the area of the specific targeted treatment. Recently,
targeted therapy has mainly included immunotoxins [43,
44], bispecific antibodies [45, 46], Nano-agents [47], ultra-
sound and microbubbles [48], and other specific inhibitors
[49]. The CCR9-specific antibody has presented a challenge
in terms of delivery to specific tissues due to its larger
molecular weight, hence limiting its application. Most im-
portantly, few antibodies are clinically useful as single
agents because they do not efficiently kill cancer cells [50].
To further enhance the anti-tumor efficiency and re-
duce side effects, receptor-targeted therapy has been
developed [51]. CCR9-based targeted therapy mainly
involves an immunotoxin-CCL25 combination that
has a small molecular weight and a high specificity.
Its chemotactic ability to target cells makes it useful
in the targeted therapy of CCR9+ malignant cancers
with good prospects for application.
We previously developed a CCL25-PE38 fusion pro-
tein using genetic engineering. PE38 is a derivative of
Pseudomonas exotoxin A (PE). PE38 is composed of
domains II and III of PE; domain II (278 to 389 bp) con-
tains a furin cleavage site, while domain III (430 to
638 bp) has ADP-ribosylating activity [52]. When the
ligand binds with its specific receptor, the immunotoxin
is internalized via the endolysosomal system to the Golgi
apparatus and is further transported to the endoplasmic
reticulum, where PE38 is activated through reduction of
a disulfide bond and cleavage by the protease furin at a
site that separates the Fv from the catalytic fragment of
PE38. Subsequently, the activated PE38 translocate to
the cytosol, where it ADP-ribosylates and inactivates
elongation factor 2, an essential component of the trans-
lation apparatus, thus halting protein synthesis and
eventually leading to cell death [53]. The mechanism of
PE38 action is shown in Fig. 5 [54].
Our results demonstrated that CCL25-PE38 is able to
specifically kill MOLT4 cells via induction of apoptosis.
This result suggests that CCL25-PE38 could suppress
the growth of CCR9-positive cancers, as CCR9-high-
expressing human T-ALL cells underwent apoptosis
when exposed to a PE38 toxin fused to a CCL25 ligand.
However, it can be said that it cannot completely
Fig. 4 Diagram summarizing the reviewed mechanisms by which CCR9 induces different aspects of tumor chemoresistance and metastasis. The
solid arrows indicate that these signaling pathways have confirmed; the dashed arrows show that these signaling pathways need to be
further validation
Tu et al. Journal of Hematology & Oncology  (2016) 9:10 Page 6 of 9
eliminate the established cancer, as some parts of the
expanding tumors do not express CCR9, thereby ren-
dering CCL25-PE38 ineffective [55].
Others
We also found that T-ALL cells can increase the expres-
sion of IL-4 after treatment with IL-2 and that IL-2 can
activate the PKC and GRK2 signaling pathways to in-
duce CCR9 internalization, thereby reducing leukemia
cell infiltration and metastasis [56].
Conclusions
CCL25/CCR9, as a member of the CC chemokines and
their receptors, is known to be involved in chemotac-
tic cells, lymphocyte development, survival, prolifera-
tion, and migration. Recently, researchers have found
that CCL25/CCR9 plays an important role in tumori-
genesis and is mainly involved in tumor chemoresis-
tance and metastasis, which hamper the effects of
conventional surgery, radiotherapy, and chemother-
apy. Therefore, CCR9 has become a potential targeted
molecule for cancer therapy because it is highly
expressed in various cancers (Table 1). Targeting ther-
apy drugs can be delivered into exact positions and
can then be gradually released, thus reducing drug sys-
temic side effects with enhanced antitumor efficiency
[57]. Nevertheless, substantial work is still required,
and future research efforts will provide us with a
pharmacological basis of the therapeutic use of tar-
geted therapy in cancer and a basis for the further
investigation of other potential anti-CCR9 agents.
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